New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Ipamorelin

Pancragen vs Ipamorelin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Growth Hormone Peptides
Ipamorelin
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
Half-Life
Short (minutes); sustained gene-regulatory effects
2 hours
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
100–300 mcg
Frequency
Daily for 10–30 days
Once to twice daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Increases lean muscle mass
  • Enhances fat loss
  • Improves recovery time
  • Strengthens bones and joints
  • Better sleep quality and REM sleep
  • Enhanced skin elasticity
  • Minimal impact on hunger or cortisol
  • No cortisol or prolactin spike
  • Clean GH release suitable for long-term protocols
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Injection site irritation
  • Temporary water retention (mild)
  • Possible hunger increase (milder than GHRP-6)
  • Numbness or tingling in extremities (rare)
Stacks With